- Organic Dyspepsia
- Non-Ulcer Dyspepsia
- Drug-Induced Dyspepsia
Dyspepsia Market size was valued at USD 9,326.8 million in 2023 and is poised to grow at 4.5% CAGR over the forecast period 2024–2030. Dyspepsia, also known as indigestion, encompasses a range of upper abdominal discomfort or pain, often accompanied by bloating, belching, and nausea. It is a common gastrointestinal disorder that can significantly impact individuals quality of life. According to the World Health Organization (WHO) and the National Institutes of Health (NIH), dyspepsia affects a substantial portion of the global population and it was estimated that around 25-40% of adults experienced dyspeptic symptoms at least occasionally. These symptoms may result from various underlying causes, including gastroesophageal reflux disease (GERD), peptic ulcers, gastritis, and functional dyspepsia.
Functional dyspepsia, a subtype of dyspepsia with no identifiable structural or biochemical abnormalities, has been a subject of particular interest. Studies suggest that it affects approximately 10-20% of the population in Western countries. The burden of dyspepsia is not limited to its prevalence alone it also contributes to a substantial economic impact due to healthcare utilization, including doctor visits, diagnostic tests, and treatments. In the United States, for instance, direct and indirect costs associated with functional dyspepsia have been estimated to be in the billions of dollars annually. Furthermore, dyspepsia is often linked to lifestyle factors such as diet, stress, and smoking. Obesity, too, is a contributing factor, as it can exacerbate symptoms and increase the risk of GERD. While lifestyle modifications and dietary changes are recommended as initial management strategies, pharmacological interventions may also be necessary for some individuals.
Study Period
2024-2030Base Year
2023CAGR
4.5%Largest Market
North AmericaFastest Growing Market
Asia Pacific
Dyspepsia, a prevalent gastrointestinal disorder, is poised for dynamic market growth driven by several key factors. Increasing awareness about digestive health, coupled with a rising aging population, is fostering a higher demand for effective dyspepsia management. Lifestyle changes, including unhealthy dietary habits, contribute to the growing incidence of dyspepsia, further propelling market expansion. The pharmaceutical sector's focus on developing innovative and targeted therapies, alongside advancements in diagnostic technologies, creates opportunities for improved treatment options. Additionally, the surge in research activities surrounding novel drug compounds and natural remedies enhances the potential for market evolution. The integration of telemedicine and digital health platforms also facilitates easier access to medical consultation, driving market accessibility. In conclusion, dyspepsia's market dynamics are underpinned by robust growth drivers and a plethora of opportunities, promising a thriving landscape for both the pharmaceutical and healthcare sectors.
By Type
By Drug Type
By Prescription
By Route of Administration
By Distribution Channel
By Geography
The Dyspepsia market was valued at USD 9,326.8 million in 2022 and is expected to grow at 4.5% CAGR over the forecast period 2023 – 2029.
The Dyspepsia market presents promising prospects driven by growing awareness, innovative diagnostic technologies, and expanding healthcare infrastructure. Personalized treatments, novel therapies, and patient-centric approaches offer avenues for advancement and improved patient outcomes.
Rising focus on non-invasive diagnostic methods, increasing prevalence of lifestyle-related digestive disorders, adoption of precision medicine, and integration of telehealth solutions shape Dyspepsia market trends for enhanced diagnosis and patient care.
Bayer AG, Mankind Pharma, Cadila Pharmaceuticals., Salix Pharmaceuticals, Sanofi, Aosaikand Pharmaceutical Co., Ltd., Hanmi Pharm. Co., Ltd., Lupin. RedHill Biopharma Ltd., Abbott. and Prestige Consumer Healthcare Inc. among others are a few prominent companies operating in the field of Dyspepsia market.
1.Executive Summary |
2.Global Dyspepsia Market Introduction |
2.1.Global Dyspepsia Market - Taxonomy |
2.2.Global Dyspepsia Market - Definitions |
2.2.1.Type |
2.2.2.Drug Type |
2.2.3.Prescription |
2.2.4.Route of Administration |
2.2.5.Region |
3.Global Dyspepsia Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4.Global Dyspepsia Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5.Global Dyspepsia Market By Type , 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
5.1. Organic Dyspepsia |
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Non-Ulcer Dyspepsia |
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Drug-Induced Dyspepsia |
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
6.Global Dyspepsia Market By Drug Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
6.1. Branded |
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Generic |
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
7.Global Dyspepsia Market By Prescription, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
7.1. Prescription Drugs |
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. OTC Drugs |
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
8.Global Dyspepsia Market By Route of Administration , 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
8.1. Oral |
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Injectable |
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
9.Global Dyspepsia Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
9.1. North America |
9.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
9.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.1.3. Market Opportunity Analysis |
9.2. Europe |
9.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
9.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.2.3. Market Opportunity Analysis |
9.3. Asia Pacific (APAC) |
9.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
9.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.3.3. Market Opportunity Analysis |
9.4. Middle East and Africa (MEA) |
9.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
9.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.4.3. Market Opportunity Analysis |
9.5. Latin America |
9.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
9.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.5.3. Market Opportunity Analysis |
10.North America Dyspepsia Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
10.1. Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.Organic Dyspepsia |
10.1.2.Non-Ulcer Dyspepsia |
10.1.3.Drug-Induced Dyspepsia |
10.2. Drug Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1. Branded |
10.2.2. Generic |
10.3. Prescription Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1. Prescription Drugs |
10.3.2. OTC Drugs |
10.4. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.4.1. Oral |
10.4.2. Injectable |
10.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.5.1.United States of America (USA) |
10.5.2.Canada |
11.Europe Dyspepsia Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
11.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.Organic Dyspepsia |
11.1.2.Non-Ulcer Dyspepsia |
11.1.3.Drug-Induced Dyspepsia |
11.2. Drug Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1. Branded |
11.2.2. Generic |
11.3. Prescription Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1. Prescription Drugs |
11.3.2. OTC Drugs |
11.4. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.4.1. Oral |
11.4.2. Injectable |
11.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.5.1.Germany |
11.5.2.France |
11.5.3.Italy |
11.5.4.United Kingdom (UK) |
11.5.5.Spain |
12.Asia Pacific (APAC) Dyspepsia Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
12.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.Organic Dyspepsia |
12.1.2.Non-Ulcer Dyspepsia |
12.1.3.Drug-Induced Dyspepsia |
12.2. Drug Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1. Branded |
12.2.2. Generic |
12.3. Prescription Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1. Prescription Drugs |
12.3.2. OTC Drugs |
12.4. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.4.1. Oral |
12.4.2. Injectable |
12.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.5.1.China |
12.5.2.India |
12.5.3.Australia and New Zealand (ANZ) |
12.5.4.Japan |
12.5.5.Rest of APAC |
13.Middle East and Africa (MEA) Dyspepsia Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
13.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.1.1.Organic Dyspepsia |
13.1.2.Non-Ulcer Dyspepsia |
13.1.3.Drug-Induced Dyspepsia |
13.2. Drug Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.2.1. Branded |
13.2.2. Generic |
13.3. Prescription Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.3.1. Prescription Drugs |
13.3.2. OTC Drugs |
13.4. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.4.1. Oral |
13.4.2. Injectable |
13.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.5.1.GCC Countries |
13.5.2.South Africa |
13.5.3.Rest of MEA |
14.Latin America Dyspepsia Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
14.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.1.1.Organic Dyspepsia |
14.1.2.Non-Ulcer Dyspepsia |
14.1.3.Drug-Induced Dyspepsia |
14.2. Drug Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.2.1. Branded |
14.2.2. Generic |
14.3. Prescription Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.3.1. Prescription Drugs |
14.3.2. OTC Drugs |
14.4. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.4.1. Oral |
14.4.2. Injectable |
14.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.5.1.Brazil |
14.5.2.Mexico |
14.5.3.Rest of LA |
15. Competition Landscape |
15.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
15.2.1.Bayer AG |
15.2.2.Mankind Pharma |
15.2.3.Cadila Pharmaceuticals |
15.2.4.Salix Pharmaceuticals |
15.2.5.Sanofi |
15.2.6.Aosaikand Pharmaceutical Co., Ltd. |
15.2.7.Hanmi Pharm. Co., Ltd. |
15.2.8.Lupin |
15.2.9.RedHill Biopharma Ltd. |
15.2.10.Abbott |
15.2.11.Prestige Consumer Healthcare Inc. |
16. Research Methodology |
17. Appendix and Abbreviations |